Go Pro

Michael King Analyst Performance

Analyst at Rodman & Renshaw

Michael King is a stock analyst at Rodman & Renshaw in the healthcare sector, covering 20 publicly traded companies. Over the past year, Michael King has issued 10 stock ratings, including strong buy and buy recommendations. While full access to Michael King's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael King's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
44 Last 10 Years
Buy Recommendations
100.00% 44 Buy Ratings
Companies Covered
20 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy4.5%2 ratings
Buy95.5%42 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

Out of 44 total stock ratings issued by Michael King at Rodman & Renshaw, the majority (95.5%) have been Buy recommendations, followed by 4.5% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
20 companies

Michael King, an analyst at Rodman & Renshaw, currently covers 20 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
20 companies
100.0%

Michael King of Rodman & Renshaw specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
17 companies
85.0%
PHARMACEUTICALS
3 companies
15.0%

Michael King's Ratings History at Rodman & Renshaw

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
8/31/2026Initiated Coverage$3.08$8.00Buy
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
7/30/2026Initiated Coverage$1.08$6.00Buy
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
7/7/2026Initiated Coverage$2.28$12.00Buy
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
6/9/2026Initiated Coverage$6.63$30.00Buy
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
5/28/2026Initiated Coverage$5.39$22.00Buy
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
3/17/2026Initiated Coverage$1.54$17.00Buy
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
3/10/2026Upgrade$12.16Strong-Buy
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3/10/2026Upgrade$8.55Strong-Buy
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3/9/2026Initiated Coverage$8.49$28.00Buy
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
3/9/2026Initiated Coverage$11.63$17.00Buy